Long-term treatment with tamoxifen activates MAP kinase and mTOR pathway and enhances interaction between growth factor receptor and ERα in breast cancer cells.

被引：0
|
作者：
Fan, P
Yue, W
Wang, J
机构：
[1] Nanjing Med Univ, Nanjing, Peoples R China
[2] Univ Virginia, Charlottesville, VA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：84S / 84S
页数：1
相关论文
共 50 条
  • [21] Palbociclib treatment activates FAK and use of palbociclib in combination with the FAK inhibitor PF-562,271 enhances antitumor activity in ER-positive breast cancer cells.
    Howe, Grant
    Allen, Victoria
    Addison, Christina L.
    MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 80 - 81
  • [22] Inhibition of focal adhesion kinase (FAK) and epidermal growth factor receptor (EGFR) signaling synergistically increase apoptosis in human breast cancer cells.
    Golubovskaya, V
    Beviglia, L
    Xu, L
    Earp, H
    Cance, W
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3719S - 3719S
  • [23] Bisphenol a Interacts with Gper, Activates EGFR and ERK Signaling and Antagonizes Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Breast Cancer Cells
    Sauer, Scott Jeffrey
    Davis, John B.
    Lyerly, H. Kim
    Shah, Imran
    Williams, Kevin P.
    Devi, Gayathri R.
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [24] Inhibition of phosphoinositide 3-kinase enhances the cytotoxicity of AG1478, an epidermal growth factor receptor inhibitor, in breast cancer cells
    Ping Li
    Artour Torossian
    Qing Zhang
    Wen-cai Xu
    Shen Fu
    Medical Oncology, 2012, 29 : 3258 - 3264
  • [25] Inhibition of phosphoinositide 3-kinase enhances the cytotoxicity of AG1478, an epidermal growth factor receptor inhibitor, in breast cancer cells
    Li, Ping
    Torossian, Artour
    Zhang, Qing
    Xu, Wen-cai
    Fu, Shen
    MEDICAL ONCOLOGY, 2012, 29 (05) : 3258 - 3264
  • [26] Even with long-term follow-up epidermal growth factor receptor (EGFR) expression is of no prognostic value in breast cancer
    Rampaul, RS
    Pinder, SE
    Wencyk, PM
    Bell, JA
    Robertson, JFR
    Nicholson, RI
    Blamey, RW
    Ellis, IO
    JOURNAL OF PATHOLOGY, 2001, 195 : 27A - 27A
  • [27] LONG-TERM TAMOXIFEN TREATMENT OF ATHYMIC MICE IMPLANTED WITH MCF-7 BREAST-CANCER CELLS - CRITICAL IMPORTANCE OF TUMOR BURDEN
    GOTTARDIS, MM
    JORDAN, VC
    BREAST CANCER RESEARCH AND TREATMENT, 1987, 10 (01) : 85 - 85
  • [28] The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ('Iressa') enhances the antitumor effect of the antiestrogen ICI 182,780 ('Faslodex') in estrogen-receptor-positive breast cancer cells.
    Kurebayashi, J
    Okubo, S
    Yamamoto, Y
    Otsuki, T
    Sonoo, H
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S71 - S71
  • [29] Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells
    Asanuma, H
    Torigoe, T
    Kamiguchi, K
    Hirohashi, Y
    Ohmura, T
    Hirata, K
    Sato, M
    Sato, N
    CANCER RESEARCH, 2005, 65 (23) : 11018 - 11025
  • [30] EPIDERMAL GROWTH-FACTOR RECEPTORS AND EFFECT OF EPIDERMAL GROWTH-FACTOR ON GROWTH OF HUMAN-BREAST CANCER-CELLS IN LONG-TERM TISSUE-CULTURE
    IMAI, Y
    LEUNG, CKH
    FRIESEN, HG
    SHIU, RPC
    CANCER RESEARCH, 1982, 42 (11) : 4394 - 4398
12345